A series of blood tests, procedures, and imaging tests can help diagnose acute myeloid leukemia (AML). Additionally, these tests can also determine its subtype and help identify the best treatment ...
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...
The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and ...
Opinion
Retail Banker International on MSNOpinion
Validating AI-driven AML outcomes under FCA supervision
Dr Janet Bastiman discusses the future of AI for AML and offers expert guidance on how best to collaborate with the FCA and other regulators ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
1don MSN
Leukemia stem cells cause treatments to fail, but findings open new avenues to overcome resistance
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM Stem Cell Institute have deciphered a key mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results